| ²é¿´: 389 | »Ø¸´: 1 | ||
cainiaoduiгæ (СÓÐÃûÆø)
|
[ÇóÖú]
·ÒëÇóÖú
|
|
In preclinical models a number of tumors do not respond at all, or respond initially but become resistant at a late stage of VEGF inhibition . In some experimental cases, such therapy may even increase tumor invasiveness and metastasis . A further problem is that although this therapy is highly specific, patients are not selected on the basis of pathways of sensitivity or resistance in their tumors. Thus, tumor resistance to VEGF inhibition has become a major obstacle to the effectiveness of antiangiogenic agents in the clinic. Clearly, understanding the resistance mechanisms will enhance anti-VEGF efficacy by developing new therapeutic approaches or rational drug combinations |
» ²ÂÄãϲ»¶
0817 »¯Ñ§¹¤³Ì 299·ÖÇóµ÷¼Á ÓпÆÑоÀú ÓжþÇøÎÄÕÂ
ÒѾÓÐ4È˻ظ´
0854¿É¿çµ÷¼Á£¬Ò»×÷Ò»ÏîºËÐÄÂÛÎÄÎåÏîרÀû£¬Ê¡¡¢¹ú¼¶Ö¤Êé40+ÊýÒ»Ó¢Ò»287
ÒѾÓÐ5È˻ظ´
070300»¯Ñ§319Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸985£¬±¾¿Æ211£¬0817»¯Ñ§¹¤³ÌÓë¼¼Êõ319Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Î÷ÄϽ»´ó£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
½¹ÂÇ
ÒѾÓÐ11È˻ظ´
331Çóµ÷¼Á£¨0703Óлú»¯Ñ§
ÒѾÓÐ7È˻ظ´
298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
jiangguofeng
½ð³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 248
- Ó¦Öú: 41 (СѧÉú)
- ½ð±Ò: 25886.4
- ºì»¨: 25
- Ìû×Ó: 2100
- ÔÚÏß: 567.1Сʱ
- ³æºÅ: 72410
- ×¢²á: 2005-06-04
- רҵ: ºÏ³ÉÒ©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-03-24 20:39:59
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-04-04 16:05:36
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-03-24 20:39:59
cainiaodui(RXMCDM´ú·¢): ½ð±Ò+2, ¶àлӦÖú£¡ 2014-04-04 16:05:36
| ÔÚÁÙ´²Ç°Ä£ÐÍÖÐ,Ðí¶àÖ×ÁöÍêȫûÓз´Ó¦»ò×î³õÓз´Ó¦¶øÔÚѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÒÖÖÆµÄÍíÆÚÈ´±ä³É¿¹ÐԵġ£ ÔÚÓÐЩʵÑ鲡ÀýÖУ¬´ËÀàÁÆ·¨ÉõÖÁ»áÉý¸ßÖ×ÁöÇÖÏ®Á¦ºÍ×ªÒÆÄÜÁ¦¡£ ÁíÒ»¸öÎÊÌâÊÇ£¬¾¡¹ÜÕâÖÖÁÆ·¨ÊǷdz£ÓÐÌØÐ§µÄ£¬µ«ÊÇ»¼ÕßµÄÑ¡Ôñ²»ÊǸù¾ÝËûÃǵÄÖ×ÁöµÄÃô¸ÐÐÔ»ò¿¹ÐÔ·¾¶¡£ Òò´Ë,Ö×Áö¶ÔÓÚѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÒÖÖÆµÄ¿¹ÐÔÒѳÉΪÁÙ´²ÖзÁ°¿¹Ñª¹ÜÐÂÉúÒ©ÎïÁÆÐ§µÄÒ»ÖÖÖ÷ÒªÒòËØ¡£ÏÔ¶øÒ×¼û£¬Á˽âÕâÖÖ¿¹ÐÔ»úÀí½«»áͨ¹ý¿ª·¢ÐµÄÖÎÁÆ·½·¨»òºÏÀíµÄ¸´·½ºÏ¼ÁÀ´Ìá¸ßѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÒÖÖÆ¼ÁµÄ¹¦Ð§ |
2Â¥2014-03-24 20:11:41













»Ø¸´´ËÂ¥